TraMADol (Lexi-Drugs)

ALERT: US Boxed Warning
  Addiction, abuse, and misuse:
  Opioid analgesic Risk Evaluation and Mitigation Strategy (REMS):
  Life-threatening respiratory depression:
  Accidental ingestion:
  Ultra-rapid metabolism of tramadol and other risk factors for life-threatening respiratory depression in children:
  Neonatal opioid withdrawal syndrome:
  Interactions with drugs affecting cytochrome P450 isoenzymes:
  Risks from concomitant use with benzodiazepines or other CNS depressants:
Pronunciation

(TRA ma dole)

Brand Names: US

ConZip; Ultram; Ultram ER [DSC]

Brand Names: Canada

Durela; Ralivia; TARO-Tramadol ER; Tridural; Ultram; Zytram XL

Pharmacologic Category

Analgesic, Opioid

Dosing: Adult

Pain management, moderate to severe: Note: In general, opioids may be considered a potential component of a comprehensive, multimodal, patient-specific treatment plan for pain. Nonopioid analgesia should be maximized, if appropriate, prior to initiation of opioid analgesia; combination therapy with analgesics with differing mechanisms of action may improve efficacy and reduce the doses and/or frequency required for each agent (APS 2016; Hill 2018). Tramadol doses should be titrated to appropriate analgesic effect; use the lowest effective dose for the shortest period of time. Tramadol is used for a variety of moderate to moderately severe painful conditions and may be of particular benefit for patients with mixed nociceptive and neuropathic pain due to its dual mechanism of action (APS 2016).

Acute pain (eg, postoperative): Note: In patients who are experiencing acute pain severe enough to require opioids (in addition to appropriate nonopioid analgesia), limit the quantity prescribed to the expected duration of acute pain; a quantity sufficient for ≤3 days is often adequate, whereas >7 days is rarely needed (CDC [Dowell 2016]). Long-acting preparations are not recommended for treatment of acute pain in opioid-naive patients (CDC [Dowell 2016]).

Immediate release: Oral: Initial: 50 mg every 4 to 6 hours as needed (APS 2016); some experts suggest that 3 doses per day may be sufficient for patients with moderate acute pain (Pino 2018). The dose may be increased as needed and tolerated to 50 to 100 mg every 4 to 6 hours (maximum: 400 mg/day) (APS 2016; manufacturer’s labeling).

Chronic pain (alternative agent): Note: Opioids, including tramadol, are not the preferred therapy for chronic pain due to insufficient evidence of benefit and risk of serious harm; nonpharmacologic treatment and nonopioid analgesics are preferred (CDC [Dowell 2016]). Opioids, including tramadol, should only be considered in patients who experience clinically meaningful improvement in pain and function that outweighs patient safety risks (CDC [Dowell 2016]). The utility of tramadol in patients with chronic pain due to cancer is questionable, especially considering its dual mechanism of action and dose ceiling (Bandieri 2016; Wiffen 2017).

Opioid-naive patients not currently on tramadol immediate release:

Immediate release: Oral: The ideal dosing regimen has not been established; consider restricting the initial dose to <300 mg tramadol per day (ie, <50 mg morphine equivalents daily) (Busse 2017). An example initial dose is 25 to 50 mg every 6 hours as needed (Rosenquist 2018). The dose may be increased as needed and tolerated to 50 to 100 mg every 4 to 6 hours (maximum: 400 mg/day) (APS 2016; manufacturer’s labeling).

Extended release: Note: Although manufacturer’s labeling contains the following directions for initiating extended-release tramadol products in opioid-naive patients with chronic pain, it is recommended that when starting opioid therapy, treatment be initiated with an immediate-release preparation to more accurately determine the daily opioid requirement and decrease the risk of overdose (CDC [Dowell 2016]). The CDC recommends that extended-release opioids be reserved for patients who have received immediate-release opioids daily for ≥1 week yet continue to experience severe, continuous pain (CDC [Dowell 2016]).

Initial: Oral: 100 mg once daily; titrate by 100 mg/day increments every 5 days as needed (maximum: 300 mg/day)

Tridural [Canadian product]: Initial: Oral: 100 mg once daily; titrate by 100 mg/day increments every 2 days as needed (maximum: 300 mg/day)

Zytram XL [Canadian product]: Oral: 150 mg once daily; if pain relief is not achieved, may titrate by increasing dosage incrementally with sufficient time to evaluate effect of increased dosage, generally not more often than every 7 days (maximum: 400 mg/day).

Patients currently on tramadol immediate release for ≥1 week: Calculate 24-hour tramadol immediate-release total dose and initiate total extended-release daily dose (round dose to the next lowest 100 mg increment); titrate as needed and tolerated to desired effect (maximum: 300 mg/day). In patients who experience breakthrough pain, clinicians may consider the addition of an immediate-release rescue analgesic (eg, NSAID or short-acting weak opioid).

Discontinuation of therapy: When discontinuing chronic opioid therapy, the dose should be gradually tapered down. An optimal universal tapering schedule for all patients has not been established (CDC [Dowell 2016]). Proposed schedules range from slow (eg, 10% reductions per week) to rapid (eg, 25% to 50% reduction every few days) (CDC 2015). Tapering schedules should be individualized to minimize opioid withdrawal while considering patient-specific goals and concerns as well as the pharmacokinetics of the opioid being tapered. An even slower taper may be appropriate in patients who have been receiving opioids for a long duration (eg, years), particularly in the final stage of tapering, whereas more rapid tapers may be appropriate in patients experiencing severe adverse events (CDC [Dowell 2016]). Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, pausing the taper and restarting when the patient is ready, and/or coadministration of an alpha-2 agonist (eg, clonidine) to blunt withdrawal symptoms (Berna 2015; CDC [Dowell 2016]; manufacturer’s labeling). Continue to offer nonopioid analgesics as needed for pain management during the taper; consider nonopioid adjunctive treatments for withdrawal symptoms (eg, GI complaints, muscle spasm) as needed (Berna 2015; Sevarino 2018).

Premature ejaculation (alternative agent) (off-label use): Note: Tramadol may be considered in patients who have failed other therapies (eg, SSRIs, topical anesthetics). Consideration should be given to the risk of addiction and adverse effects associated with opioids (ISSM [Althof 2014]); to promote safe use, regular follow-up to monitor for response, toxicity, and misuse is recommended.

Immediate release: Oral: The ideal dosing regimen has not been established; dosage range studied: 25 to 50 mg administered on demand 1 to 3 hours prior to intercourse (Alghobary 2010; Eassa 2013; Gameel 2013; Kaynar 2012; Safarinejad 2006; Salem 2008).

Restless legs syndrome, refractory (alternative agent) (off-label use): Note: Use of opioids for restless legs syndrome (RLS) is typically restricted to patients with severe symptoms refractory to first-line agents for RLS (Silber 2018). Consideration should be given to the risk of addiction and adverse effects associated with opioids; to promote safe use, regular follow-up to monitor for response, toxicity, and misuse is recommended. Clinicians should note that the adverse effect of RLS augmentation (ie, worsening of symptoms) has been reported with tramadol use (Earley 2006; Vetrugno 2007).

Immediate release: Oral: Initial: 50 mg once daily at bedtime or during the night; titrate to the lowest effective dose (Silber 2018). Usual effective dosage range: 50 to 100 mg/day (Silber 2013).

Extended release: Oral: Initial: 100 mg once daily at bedtime or during the night; titrate to the lowest effective dose. Usual effective dosage range: 100 to 200 mg/day (Silber 2018). Note: Extended-release formulations may be preferred to decrease end-of-dose rebound; consider conversion to an extended-release formulation after establishment of efficacy and tolerability (≥7 days based on chronic pain recommendations [CDC (Dowell 2016)]) with an immediate-release formulation (Silber 2018).

Dosing: Geriatric

Elderly >65 years to ≤75 years: Refer to adult dosing; use with caution and initiate at the low end of the dosing range.

Elderly >75 years:

Immediate release: Maximum: 300 mg/day.

Extended release: Use with extreme caution.

Dosing: Renal Impairment: Adult

Immediate release:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

CrCl <30 mL/minute: Increase dosing interval to every 12 hours (maximum: 200 mg/day).

Dialysis: Dialyzable (7%); increase dosing interval to every 12 hours; (maximum: 200 mg/day); administer regular dose on the day of dialysis.

Extended release:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

CrCl <30 mL/minute: Avoid use.

Dosing: Hepatic Impairment: Adult

Immediate release: There are no dosage adjustments provided in the manufacturer’s labeling. In patients with cirrhosis, recommended dose is 50 mg every 12 hours.

Extended release:

Mild to moderate impairment (Child-Pugh class A and B): There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Severe impairment (Child-Pugh class C): Avoid use.

Dosing: Pediatric

Note: Doses should be titrated to appropriate analgesic effect; use the lowest effective dose for the shortest period of time:

Moderate to severe pain (excluding postoperative tonsillectomy/adenoidectomy pain): Note: The FDA has recommended that tramadol not be used in pediatric patients <12 years of age and all pediatric patients undergoing tonsillectomy and/or adenoidectomy due to increased risk of breathing problems (sometimes fatal). Slowed or difficult breathing has been reported in pediatric patients <18 years of age; risk may be increased in pediatric patients who are obese or have conditions such as obstructive sleep apnea or severe lung disease, or who are ultrarapid metabolizers of the drug (FDA 2015; FDA 2017).

Immediate release formulations:

Immediate release tablet:

Children and Adolescents 4 to ≤16 years: Limited data available: Oral: 1 to 2 mg/kg/dose every 4 to 6 hours; maximum single dose: 100 mg (usual adult starting dose: 50 to 100 mg); maximum daily dose is the lesser of 8 mg/kg/day or 400 mg/day (Finkel 2002; Payne 2002; Rose 2003). Note: Due to potential respiratory complications, tramadol should be avoided in patients <12 years of age and all pediatric patients undergoing tonsillectomy and/or adenoidectomy (FDA 2017).

Adolescents ≥17 years: Oral: 50 to 100 mg every 4 to 6 hours; maximum daily dose: 400 mg/day. For patients not requiring rapid onset of effect, tolerability to adverse effects may be improved by initiating therapy at 25 mg/day and titrating dose by 25 mg every 3 days until 25 mg 4 times daily is reached. Dose may then be increased by 50 mg every 3 days as tolerated to reach 50 mg 4 times daily.

Orally disintegrating tablet (eg, Rybix ODT): Adolescents ≥17 years: Oral: 50 to 100 mg every 4 to 6 hours; maximum total daily dose: 400 mg/day. For patients not requiring rapid onset of effect, tolerability to adverse effects may be improved by initiating therapy at 50 mg/day and titrating dose by 50 mg every 3 days until 50 mg 4 times/day is reached; maximum total daily dose: 400 mg/day

Extended release formulations (eg, Conzip, Ultram ER): Oral: Note: For patients requiring around-the-clock pain management for an extended period of time; Adolescents ≥18 years:

Patients not currently on immediate release tramadol: 100 mg once daily; titrate every 5 days; maximum daily dose: 300 mg/day

Patients currently on immediate release tramadol: Calculate 24-hour total immediate release tramadol dose and initiate total extended release daily dose (round dose to the next lowest 100 mg increment) once daily; titrate as tolerated to desired effect; maximum daily dose: 300 mg/day

Dosing: Renal Impairment: Pediatric

Immediate release: Adolescents ≥17 years:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

CrCl <30 mL/minute: Increase dosing interval to every 12 hours; maximum daily dose: 200 mg/day.

Dialysis: Dialyzable (7%); increase dosing interval to every 12 hours; maximum daily dose: 200 mg/day; administer regular dose on the day of dialysis.

Extended release: Adolescents ≥18 years:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

CrCl <30 mL/minute: Avoid use.

Dosing: Hepatic Impairment: Pediatric

Immediate release: Adolescents ≥17 years: There are no dosage adjustments provided in the manufacturer’s labeling. In patients with cirrhosis, recommended dose is 50 mg every 12 hours.

Extended release: Adolescents ≥18 years:

Mild to moderate impairment (Child-Pugh class A and B): There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Severe impairment (Child-Pugh class C): Avoid use.

Use: Labeled Indications

Pain management:

Extended release: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Immediate release: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of use: Reserve tramadol for use in patients for whom alternative treatment options (eg, nonopioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Tramadol ER is not indicated as an as-needed analgesic.

Use: Off-Label: Adult

  Premature ejaculationLevel of Evidence [B, G]

Data from mostly placebo-controlled clinical trials suggest that tramadol may be beneficial for the treatment of premature ejaculation Ref.

Based on the International Society of Sexual Medicine (ISSM) guidelines for the diagnosis and treatment of premature ejaculation, tramadol may be considered an alternative treatment option in patients who have experienced treatment failure with other therapies due to the risk of addiction and adverse effects associated with use Ref.

  Restless legs syndrome, refractoryLevel of Evidence [C, G]

Data from a small noncontrolled trial suggest that tramadol may be beneficial in the treatment of restless legs syndrome (RLS) Ref.

American Academy of Sleep Medicine guidelines on the treatment of RLS and periodic limb movement disorder (PLMD) in adults consider opioids effective based on low-level evidence Ref. American Academy of Neurology guidelines on the treatment of RLS in adults recommend that a specific opioid/opioid antagonist combination agent (does not include tramadol) may be considered in patients with RLS that has not responded to other treatments, but note that the benefit of treatment with opioids should be weighed against the known risks of these agents Ref. European Federation of Neurological Societies/European Neurological Society/European Sleep Research Society joint task force guidelines on the management of RLS consider data insufficient to make a recommendation regarding opioids. These guidelines also note the first case report (involving tramadol) of RLS augmentation with opioids RefAccess Full Off-Label Monograph

Level of Evidence Definitions
  Level of Evidence Scale
Clinical Practice Guidelines

Diabetic Neuropathy:

Neurology, “Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy,” April 2011

Osteoarthritis:

American College of Rheumatology, “Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,” 2012

Patient Safety:

“CDC Guideline for Prescribing Opioids for Chronic Pain,” 2016

Administration: Oral

Immediate release: Administer without regard to meals.

Extended release: Swallow whole; do not crush, chew, dissolve, or split.

ConZip: Administer without regard to meals.

Ultram ER: Administer without regard to meals, but administer in a consistent manner of either with or without meals.

Canadian products:

Durela, Ralivia, Zytram XL: Administer without regard to meals.

Tridural: Administer once daily with breakfast.

Administration: Pediatric

Oral:

Immediate-release tablet: May administer with or without food, but it is recommended that it be administered in a consistent manner.

Extended-release tablet: Swallow whole with a sufficient amount of liquid. Do not crush, cut, dissolve, or chew extended-release tablet; may be taken without regard to meals; tablet should be taken once daily at approximately the same time each day.

Dietary Considerations

Some products may contain phenylalanine.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Extemporaneously Prepared

A 5 mg/mL oral suspension may be made with tablets and either Ora-Sweet® SF or a mixture of 30 mL Ora-Plus® and 30 mL strawberry syrup. Crush six 50 mg tramadol tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to almost 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label “shake well before use”. Stable for 90 days refrigerated or at room temperature.

Wagner DS, Johnson CE, Cichon-Hensley BK, et al, “Stability of Oral Liquid Preparations of Tramadol in Strawberry Syrup and a Sugar-Free Vehicle,” Am J Health Syst Pharm, 2003, 60(12):1268-70.[PubMed 12845924]

Medication Patient Education with HCAHPS Considerations

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience constipation, flushing, diarrhea, dry mouth, headache, itching, nausea, vomiting, or insomnia. Have patient report immediately to prescriber signs of depression (suicidal ideation, anxiety, emotional instability, or confusion), signs of Stevens-Johnson syndrome/toxic epidermal necrolysis (red, swollen, blistered, or peeling skin [with or without fever]; red or irritated eyes; or sores in mouth, throat, nose, or eyes), signs of serotonin syndrome (dizziness, severe headache, agitation, hallucinations, tachycardia, abnormal heartbeat, flushing, tremors, sweating a lot, change in balance, severe nausea, or severe diarrhea), signs of adrenal gland problems (severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss), sexual dysfunction (males), amenorrhea, decreased libido, infertility, severe dizziness, passing out, seizures, confusion, severe loss of strength and energy, angina, tachycardia, difficult urination, polyuria, difficulty breathing, slow breathing, shallow breathing, noisy breathing, severe fatigue, or vision changes (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Medication Safety Issues
  Sound-alike/look-alike issues:
  High alert medication:
  International issues:
REMS Components

Opioids for analgesic use: Elements to Assure Safe Use; Medication Guide

REMS Programs
Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

ConZip: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022370s016s017lbl.pdf#page=34

Ultram: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020281s042s043lbl.pdf#page=45

Ultram ER: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021692s015lbl.pdf#page=36

Contraindications

Hypersensitivity (eg, anaphylaxis) to tramadol, opioids, or any component of the formulation; pediatric patients <12 years; postoperative management in pediatric patients <18 years who have undergone tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma in the absence of appropriately monitored settings and/or resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected); concomitant use with or within 14 days following MAO inhibitor therapy.

Canadian products: Additional contraindications (not in US labeling): (Note: Contraindications may differ between product labeling; refer also to product labeling): Severe renal impairment (CrCl <30 mL/minute), severe hepatic impairment (Child-Pugh class C); mild, intermittent or short-duration pain that can be managed with other pain medication; management of perioperative pain; status asthmaticus, chronic obstructive airway, acute respiratory depression, hypercapnia, cor pulmonale, delirium tremens, seizure disorder, severe CNS depression, increased cerebrospinal or intracranial pressure, head injury, suspected surgical abdomen (eg, acute appendicitis or pancreatitis); acute intoxication with ethanol, hypnotics, centrally acting analgesics, opioids, or psychotropic drugs; breastfeeding, pregnancy; use during labor and delivery.

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactoid reactions: Serious anaphylactoid reactions (including rare fatalities) often following initial dosing have been reported. Pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome have also been reported. Previous anaphylactoid reactions to opioids may increase risks for similar reactions to tramadol; avoid use in these patients. If anaphylaxis or other hypersensitivity occurs, discontinue permanently; do not rechallenge.

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

• Hypoglycemia: Hypoglycemia (including severe cases) has been reported (rare) particularly within the first 30 days of tramadol initiation (Fournier 2015).

• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.

• Respiratory depression: [US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow ER tablets whole; crushing, chewing, or dissolving can cause rapid release and a potentially fatal dose. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

• Seizures: Even when taken within the recommended dosage seizures may occur; risk is increased in patients receiving serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), anorectics, other opioids, tricyclic antidepressants and other tricyclic compounds (eg, cyclobenzaprine, promethazine), neuroleptics, MAO inhibitors, other drugs which may lower seizure threshold, or drugs which impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Patients with a history of seizures, or with a risk of seizures (head trauma, metabolic disorders, CNS infection, malignancy, or during alcohol/drug withdrawal) are also at increased risk.

• Serotonin syndrome: May occur with concomitant use of serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs), lithium, St John’s wort, agents that impair metabolism of serotonin (eg, MAO inhibitors), or agents that impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Monitor patients for serotonin syndrome such as mental status changes (eg, agitation, hallucinations, coma); autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia); neuromuscular changes (eg, hyperreflexia, incoordination); and/or GI symptoms (eg, nausea, vomiting, diarrhea).

Disease-related concerns:

• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.

• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).

• Biliary tract impairment: Use caution in patients with biliary tract dysfunction or acute pancreatitis; opioids may cause spasm of the sphincter of Oddi.

• CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO2 retention.

• Delirium tremens: Use with caution in patients with delirium tremens.

• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.

• Hepatic impairment: Use with caution; extended-release formulations should not be used in severe hepatic impairment (Child-Pugh class C).

• Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (CDC [Dowell 2016]).

• Obesity: Use with caution in patients who are morbidly obese.

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.

• Psychosis: Use with caution in patients with toxic psychosis.

• Renal impairment: Use with caution; reduce dosage of immediate-release formulations in patients with severe renal impairment; extended-release formulations should be avoided in severe renal impairment.

• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.

• Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2016]).

• Suicide risk: Avoid use in patients who are suicidal; use with caution in patients taking tranquilizers and/or antidepressants, or those with an emotional disturbance including depression. Consider the use of alternative nonopioid analgesics in these patients.

• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.

Concurrent drug therapy issues:

• Benzodiazepines or other CNS depressants: [US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tramadol and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.

• CYP P450 interactions: [US Boxed Warning]: The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol requires careful consideration of the effects on the parent drug, tramadol, and the active metabolite, M1.

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.

• CYP2D6 “ultrarapid metabolizers”: Avoid use in patients who are ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications donated as *1/*1xN or *1/*2xN); these patients may have extensive conversion to its active metabolite and thus increased opioid-mediated effects. The occurrence of this phenotype is seen in approximately 1% to 2% of East Asians (Chinese, Japanese, Korean), 1% to 10% of Caucasians, 3% to 4% of African-Americans, and may be >10% in certain racial/ethnic groups (ie, Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican).

• Elderly: Use opioids for chronic pain with caution in older adults; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (CDC [Dowell 2016]). Consider the use of alternative nonopioid analgesics in these patients.

• Neonates: Neonatal withdrawal syndrome: [US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.

• Pediatric: [US Boxed Warning]: Life-threatening respiratory depression and death have occurred in children who received tramadol. Some of the reported cases occurred following tonsillectomy and/or adenoidectomy; in at least 1 case, the child had evidence of being an ultra-rapid metabolizer of tramadol due to a CYP450 2D6 polymorphism. Tramadol is contraindicated in pediatric patients <12 years and in pediatric patients <18 years following tonsillectomy and/or adenoidectomyAvoid the use of tramadol in pediatric patients 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of tramadol. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression. Deaths have also occurred in breastfeeding infants after being exposed to high concentrations of morphine because the mothers were ultra-rapid metabolizers of codeine.

Other warnings/precautions:

• Abuse/misuse/diversion: [US Boxed Warning]: Use exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient’s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions. Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other risk factors associated with increased risk include a personal or family history of substance use disorder or mental illness (eg, major depression). Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (≥50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (CDC [Dowell 2016]).

• Accidental ingestion: [US Boxed Warning]: Accidental ingestion of even one dose of tramadol, especially in children, can result in a fatal overdose of tramadol.

• Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should not be used as first-line therapy for chronic pain management (pain >3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to ≥50 morphine milligram equivalents (MME)/day orally; dosages ≥90 MME/day orally should be avoided unless carefully justified (CDC [Dowell 2016]).

• Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient’s needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.

• REMS program: [US Boxed Warning]: To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, a REMS is required. Drug companies with approved opioid analgesic products must make REMS-compliant education programs available to health care providers. Health care providers are encouraged to complete a REMS-compliant education program; counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products; emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist; and consider other tools to improve patient, household, and community safety.

• Surgery: Opioids decrease bowel motility; monitor for decrease bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.

• Withdrawal: Tolerance or drug dependence may result from extended use (withdrawal symptoms have been reported); abrupt discontinuation should be avoided. Tapering of dose at the time of discontinuation limits the risk of withdrawal symptoms. Concurrent use of mixed agonist/antagonist (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may also precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists.

Geriatric Considerations

One study in the elderly found that tramadol 50 mg was similar in efficacy as acetaminophen 300 mg with codeine 30 mg. In Ultram ER trials, elderly patients experienced more adverse effects than younger adults, particularly constipation, fatigue, weakness, postural hypotension, and dyspepsia. In Conzip trials, elderly patients also experienced more side effects than younger adults. For this reason, the extended release formulations should probably be avoided in the elderly, or only used with great caution. Some studies have observed an increased risk of motor-vehicle accidents with tramadol use (Rudisill 2016a; Bachs 2009); in a case-crossover study involving only older adult drivers ≥65 years, risk of motor-vehicle accidents was significantly increased in those exposed to tramadol (Rudisill 2016b).

Warnings: Additional Pediatric Considerations

Tramadol may cause slowed or difficult breathing, including fatal respiratory depression. In April 2017, the FDA announced tramadaol use should be avoided in all pediatric patients less than 12 years and all pediatric patients undergoing tonsillectomy or adenoidectomy. Additionally, tramadol should be avoided in pediatric patients 12 to 18 years who are obese or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems. The FDA is requiring updated manufacturer labeling to include in the following contraindications: Use in patients <12 years to treat pain and use in patients <18 years to treat postoperative tonsillectomy/adenoidectomy pain (FDA 2017). Patients who are ultrarapid metabolizers of CYP2D6 are thought to produce more active opioid metabolites, potentially increasing risk for adverse effects. A case report describes a 5-year old who underwent adenotonsillectomy for obstructive sleep apnea syndrome (OSAS) who experienced severe respiratory depression after taking a single dose of tramadol; the patient was found to be an ultrarapid metabolizer of CYP2D6 which potentially added to the inherent increased risk for opioid-induced respiratory depression that patients with OSAS have (Orliaguet 2015).

Pregnancy Considerations

[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.

Tramadol crosses the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to Infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.

Agents other than tramadol are commonly used to treat maternal pain during labor and immediately postpartum (ACOG 177 2017) as well as chronic noncancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).

Breast-Feeding Considerations

Tramadol and the active M1 metabolite are present in breast milk. M1 has stronger opioid activity than tramadol. Actual exposure to a breastfeeding infant may depend on the mothers CYP2D6 metabolism (Salman 2011).

Tramadol is not recommended for use in breastfeeding women. When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.

Lexicomp Pregnancy & Lactation, In-Depth
Briggs’ Drugs in Pregnancy & Lactation
Adverse Reactions

>10%:

Central nervous system: Dizziness (≤33%), vertigo (≤33%), headache (12% to 32%), drowsiness (7% to 25%), central nervous system stimulation (7% to 14%)

Gastrointestinal: Constipation (9% to 46%), nausea (16% to 40%), vomiting (5% to 17%), xerostomia (5% to 13%), dyspepsia (1% to 13%)

Neuromuscular & skeletal: Weakness (≤12%)

1% to 10%:

Cardiovascular: Flushing (8%), chest pain (1% to <5%), hypertension (1% to <5%), vasodilation (1% to <5%), peripheral edema (<5%), orthostatic hypotension (≤4%)

Central nervous system: Anxiety (1% to <5%), apathy (1% to <5%), ataxia (1% to <5%), chills (1% to <5%), confusion (1% to <5%), depersonalization (1% to <5%), depression (1% to <5%), falling (1% to <5%), feeling hot (1% to <5%), hypoesthesia (1% to <5%), lethargy (1% to <5%), nervousness (1% to <5%), pain (1% to <5%), paresthesia (1% to <5%), restlessness (1% to <5%), rigors (1% to <5%), agitation (<5%), euphoria (<5%), hypertonia (<5%), malaise (<5%), sleep disorder (<5%), withdrawal syndrome (<5%), insomnia (2%)

Dermatologic: Diaphoresis (1% to 9%), dermatitis (1% to <5%), skin rash (1% to <5%), pruritus (3%)

Endocrine & metabolic: Hot flash (1% to <5%), hyperglycemia (1% to <5%), weight loss (1% to <5%)

Gastrointestinal: Diarrhea (5% to 10%), anorexia (1% to 6%), abdominal pain (1% to <5%), decreased appetite (1% to <5%), sore throat (1% to <5%), viral gastroenteritis (1% to <5%), flatulence (<1% to <5%)

Genitourinary: Menopausal symptoms (1% to <5%), pelvic pain (1% to <5%), prostatic disease (1% to <5%), urine abnormality (1% to <5%), urinary tract infection (1% to <5%), urinary frequency (<5%), urinary retention (<5%)

Infection: Influenza (1% to <5%)

Neuromuscular & skeletal: Arthralgia (≤5%), back pain (1% to <5%), increased creatine phosphokinase (1% to <5%), limb pain (1% to <5%), myalgia (<5%), neck pain (1% to <5%), tremor (<5%)

Ophthalmic: Blurred vision (1% to <5%), miosis (1% to <5%), visual disturbance (1% to <5%)

Respiratory: Bronchitis (1% to <5%), cough (1% to <5%), nasal congestion (1% to <5%), nasopharyngitis (1% to <5%), pharyngitis (1% to <5%), rhinitis (1% to <5%), rhinorrhea (1% to <5%), sinus congestion (1% to <5%), sinusitis (1% to <5%), sneezing (1% to <5%), upper respiratory tract infection (1% to <5%)

Miscellaneous: Fever (1% to <5%), flu-like syndrome (1% to <5%), accidental injury (<5%)

<1%, postmarketing, and/or case reports (limited to important or life-threatening): Abnormal dreams, abnormal gait, abnormality in thinking, adrenocortical insufficiency, amnesia, anaphylactoid reaction, anaphylaxis, anemia, angioedema, appendicitis, arthritis, bronchospasm, cataract, cellulitis, cholecystitis, cholelithiasis, cognitive dysfunction, cold and clammy skin, deafness, decreased hemoglobin, decreased libido, delirium, difficulty in micturition, disorientation, dysgeusia, dyspnea, dysuria, ecchymoses, ECG abnormality, emotional lability, eye disease, gastroenteritis, gastrointestinal hemorrhage, gout, hair disease, hallucination, hematuria, hepatic failure, hepatitis, hyperkinesia, hypersensitivity reaction, hypoglycemia, hypotension, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased liver enzymes, increased serum ALT, increased serum AST, increased serum creatinine, irritability, ischemic heart disease, jitteriness, joint stiffness, lack of concentration, lacrimal dysfunction, lower extremity edema, menstrual disease, migraine, movement disorder, muscle cramps, muscle injury, muscle spasm, muscle twitching, mydriasis, myocardial infarction, neck stiffness, night sweats, osteoarthritis, otitis, palpitations, pancreatitis, peripheral ischemia, piloerection, pneumonia, prolonged Q-T interval on ECG, proteinuria, pulmonary edema, pulmonary embolism, sedation, seizure, serotonin syndrome, sexual difficulty, skin vesicle, speech disturbance, Stevens-Johnson syndrome, stomatitis, suicidal tendencies, syncope, tachycardia, tinnitus, toothache, torsades de pointes, urticaria viral infection, yawning

Allergy and Idiosyncratic Reactions
Toxicology
Metabolism/Transport Effects

Substrate of CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions 

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.Risk D: Consider therapy modification

Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Risk C: Monitor therapy

Amphetamines: May enhance the analgesic effect of Opioid Agonists. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor therapy

Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of TraMADol. Risk C: Monitor therapy

Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated. Risk D: Consider therapy modification

Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Risk D: Consider therapy modification

Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor therapy

Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Cannabis: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

CarBAMazepine: TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol. Risk X: Avoid combination

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol. Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of TraMADol. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of TraMADol. Risk C: Monitor therapy

Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Risk D: Consider therapy modification

Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination

Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Desmopressin: Opioid Agonists may enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. Risk C: Monitor therapy

Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk D: Consider therapy modification

Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Risk D: Consider therapy modification

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Risk D: Consider therapy modification

Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.Risk D: Consider therapy modification

Iobenguane Radiopharmaceutical Products: TraMADol may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer tramadol until at least 7 days after each iobenguane dose. Risk X: Avoid combination

Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely. Risk D: Consider therapy modification

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk C: Monitor therapy

Lorlatinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Avoid concurrent use of lorlatinib with any CYP3A4 substrates for which a minimal decrease in serum concentrations of the CYP3A4 substrate could lead to therapeutic failure and serious clinical consequences. Risk D: Consider therapy modification

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Risk D: Consider therapy modification

Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk X: Avoid combination

Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. Risk C: Monitor therapy

Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. Risk D: Consider therapy modification

Moclobemide: TraMADol may enhance the serotonergic effect of Moclobemide. This could result in serotonin syndrome. Risk X: Avoid combination

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of nalmefene and opioid agonists. Discontinue nalmefene 1 week prior to any anticipated use of opioid agonistss. If combined, larger doses of opioid agonists will likely be required. Risk D: Consider therapy modification

Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Risk D: Consider therapy modification

Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.Risk X: Avoid combination

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. Risk C: Monitor therapy

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Risk D: Consider therapy modification

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant. Risk D: Consider therapy modification

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Ritonavir: May decrease serum concentrations of the active metabolite(s) of TraMADol. Ritonavir may increase the serum concentration of TraMADol. Risk C: Monitor therapy

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Serotonin Modulators: May enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Exceptions: Nicergoline. Risk C: Monitor therapy

Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Risk D: Consider therapy modification

St John’s Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Risk D: Consider therapy modification

Succinylcholine: May enhance the bradycardic effect of Opioid Agonists. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy

Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): TraMADol may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Test Interactions

May interfere with urine detection of phencyclidine (false-positive) (Hull 2006).

Monitoring Parameters

Pain relief, respiratory and mental status, blood pressure, heart rate; bowel function; signs/symptoms of tolerance, addiction, abuse, misuse, or suicidal ideation; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)

Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (CDC [Dowell 2016]).

Reference Range

100 to 300 ng/mL; however, serum level monitoring is not required

Advanced Practitioners Physical Assessment/Monitoring

Assess patient’s physical and/or psychological dependence. Discontinue slowly after prolonged use.

Nursing Physical Assessment/Monitoring

Assess patient’s physical and/or psychological dependence. Discontinue slowly after prolonged use.

Controlled Substance

C-IV

Dosage Forms Considerations

ConZip extended release capsules are formulated as a biphasic product, providing immediate and extended release components:

100 mg: 25 mg (immediate release) and 75 mg (extended release)

200 mg: 50 mg (immediate release) and 150 mg (extended release)

300 mg: 50 mg (immediate release) and 250 mg (extended release)

EnovaRX-Tramadol and Active-Tramadol creams are compounded from kits. Refer to manufacturer’s labeling for compounding instructions.

Synapryn FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer’s labeling for compounding instructions.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule Extended Release 24 Hour, Oral, as hydrochloride:

ConZip: 100 mg, 200 mg, 300 mg [contains fd&c blue #2 aluminum lake, fd&c yellow #10 aluminum lake]

Generic: 100 mg, 150 mg, 200 mg, 300 mg

Tablet, Oral, as hydrochloride:

Ultram: 50 mg [scored; contains corn starch]

Generic: 50 mg

Tablet Extended Release 24 Hour, Oral, as hydrochloride:

Ultram ER: 100 mg [DSC], 200 mg [DSC], 300 mg [DSC]

Generic: 100 mg, 200 mg, 300 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule Extended Release 24 Hour, Oral, as hydrochloride:

Durela: 100 mg, 200 mg, 300 mg [contains FD&C BLUE #2 ALUMINUM LAKE, FD&C YELLOW #10 ALUMINUM LAKE]

Tablet, Oral, as hydrochloride:

Ultram: 50 mg

Generic: 50 mg

Tablet Extended Release 24 Hour, Oral:

Zytram XL: 75 mg [contains FD&C BLUE #2 (INDIGOTINE)]

Zytram XL: 150 mg, 400 mg

Tablet Extended Release 24 Hour, Oral, as hydrochloride:

Ralivia: 100 mg, 200 mg, 300 mg

Tridural: 100 mg, 200 mg, 300 mg

Zytram XL: 100 mg, 200 mg, 300 mg

Generic: 100 mg, 200 mg, 300 mg

Anatomic Therapeutic Chemical (ATC) Classification
  • N02AX02
Generic Available (US)

Yes

Pricing: US

Capsule ER 24 Hour Therapy Pack (ConZip Oral)

100 mg (per each): $12.66

200 mg (per each): $16.59

300 mg (per each): $22.95

Capsule ER 24 Hour Therapy Pack (traMADol HCl ER Oral)

100 mg (per each): $9.57

150 mg (per each): $9.27

200 mg (per each): $12.54

300 mg (per each): $17.34

Tablet, 24-hour (traMADol HCl ER (Biphasic) Oral)

100 mg (per each): $4.71

200 mg (per each): $7.78

300 mg (per each): $10.86

Tablet, 24-hour (traMADol HCl ER Oral)

100 mg (per each): $3.64 – $4.71

200 mg (per each): $6.02 – $7.78

300 mg (per each): $10.14 – $10.86

Tablets (traMADol HCl Oral)

50 mg (per each): $0.09 – $1.80

Tablets (Ultram Oral)

50 mg (per each): $4.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer’s AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Tramadol and its active metabolite (M1) binds to μ-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; also inhibits the reuptake of norepinephrine and serotonin, which are neurotransmitters involved in the descending inhibitory pain pathway responsible for pain relief (Grond 2004)

Pharmacodynamics/Kinetics

Onset of action: Immediate release: Within 1 hour; Peak effect: 2 to 3 hours

Distribution: Vd: IV: 2.6 L/kg (males); 2.9 L/kg (females)

Protein binding, plasma: ~20%

Metabolism: Extensively hepatic via demethylation (mediated by CYP3A4 and CYP2D6), glucuronidation, and sulfation; has pharmacologically active metabolite formed by CYP2D6 (M1; O-desmethyl tramadol)

Bioavailability:

Immediate release: ~75%

Extended release: ~85% to 95% (as compared to immediate release)

Half-life elimination:

Immediate release: 6.3 ± 1.4 hours; active metabolite (M1): 7.4 ± 1.4 hours; prolonged in elderly

Extended-release:

Capsules: ~10 hours; active metabolite (M1): ~11 hours

Tablets: ~7.9 hours; active metabolite (M1): 8.8 hours.

Time to peak, plasma:

Immediate release: ~2 hours; active metabolite (M1): 3 hours

Extended release: ~4 to 12 hours; active metabolite (M1): ~5 to 15 hours

Excretion: Urine (~30% as unchanged drug; 60% as metabolites)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Decreased rate and extent of excretion.

Hepatic function impairment:

Immediate release: Metabolism is reduced in advanced cirrhosis, resulting in increased AUC and increased elimination half-life (13 hours [tramadol], 19 hours [M1]).

Extended release: Exposure is decreased ~50% with increased severity of hepatic impairment.

Geriatric: Maximum serum concentration is increased and elimination half-life prolonged.

Gender:

Immediate release: Women had a 12% higher peak tramadol concentration and a 35% higher area under the curve (AUC) compared to men.

Extended release: AUC were somewhat higher in females than in males.

Note: Concentrations of tramadol were ~20% higher in “poor metabolizers” versus “extensive metabolizers,” while M1 concentrations were 40% lower.

Dental Use

Relief of moderate to moderately-severe dental pain

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Dental Health Professional Considerations

Based on systematic reviews evaluating benefits and harms of analgesics for acute dental pain, opioids or medication combinations containing opioids were associated with greater adverse effects. Adverse effects associated with opioid use include drowsiness, respiratory depression, dizziness, nausea, vomiting, and constipation (Moore 2018). Evidence-based recommendations for analgesic efficacy for dental pain recommend NSAIDS as the drug of choice unless contraindicated or ineffective (ADA 2016; Aminoshariae 2016). The ADA has adopted policy consistent with CDC guidelines regarding pain management; opioid prescriptions should be limited to <7 days for the treatment of acute pain (ADA 2018).

Studies have been conducted in adult patients evaluating efficacy of tramadol in the treatment of dental pain. The combination of tramadol and flurbiprofen may be more beneficial than either drug alone when given for the management of endodontic pain. Doses evaluated were flurbiprofen 100 mg loading dose, followed by 50 mg every 6 hours and tramadol 100 mg loading dose, followed by 100 mg every 6 hours (Doroschak 1999). In a comparison of tramadol/acetaminophen (total dose: 75 mg/650 mg) versus tramadol monotherapy (total dose: 100 mg) for postoperative dental pain, tramadol/acetaminophen had superior analgesic efficacy (Fricke 2004). One study showed that naproxen 500 mg was more effective than tramadol 100 mg when given as a single dose following a root canal (Mehrvarzfar 2012). In a study comparing efficacy of tramadol 100 mg and ketorolac 20 mg for the relief of pain after molar extraction, tramadol was equally effective to ketorolac (Mishra 2012).

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Xerostomia and changes in salivation (normal salivary flow resumes upon discontinuation). See Dental Health Professional Considerations.

Effects on Bleeding

No information available to require special precautions

Dental Usual Dosing

Moderate-to-severe chronic pain: Oral:

Adults:

Immediate release formulation: 50 to 100 mg every 4 to 6 hours (not to exceed 400 mg/day)

For patients not requiring rapid onset of effect, tolerability may be improved by starting dose at 25 mg/day and titrating dose by 25 mg every 3 days, until reaching 25 mg 4 times/day. The total daily dose may then be increased by 50 mg every 3 days as tolerated, to reach dose of 50 mg 4 times/day. After titration, 50 to 100 mg may be given every 4 to 6 hours as needed up to a maximum 400 mg/day.

Extended release formulations:

Ultram ER:

Patients not currently on immediate-release: 100 mg once daily; titrate every 5 days (maximum: 300 mg/day)

Patients currently on immediate-release: Calculate 24-hour immediate release total and initiate total daily dose (round dose to the next lowest 100 mg increment); titrate (maximum: 300 mg/day)

Ralivia (Canadian labeling, not available in US): 100 mg once daily; titrate every 5 days as needed based on clinical response and severity of pain (maximum: 300 mg/day)

Tridural (Canadian labeling, not available in US): 100 mg once daily; titrate by 100 mg/day every 2 days as needed based on clinical response and severity of pain (maximum: 300 mg/day)

Zytram XL (Canadian labeling, not available in US): 150 mg once daily; if pain relief is not achieved may titrate by increasing dosage incrementally, with sufficient time to evaluate effect of increased dosage; generally not more often than every 7 days (maximum: 400 mg/day)

Elderly >75 years:

Immediate release: 50 mg every 6 hours (not to exceed 300 mg/day); see dosing adjustments for renal and hepatic impairment.

Extended release formulation: Use with great caution. See adult dosing.

Index Terms

Ryzolt; Tramadol HCl; Tramadol Hydrochloride

FDA Approval Date
March 03, 1995
References

Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud el-HM, Amr M. Evaluation of tramadol on demand vs daily paroxetine as a long-term treatment of lifelong premature ejaculation. J Sex Med. 2010;7(8):2860-2867. doi: 10.1111/j.1743-6109.2010.01789.x.[PubMed 20367773]

Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2(2):60-90. doi: 10.1002/sm2.28.[PubMed 25356302]

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. Obstet Gynecol. 2017 129(4):e73-e89.[PubMed 28333819]

American Dental Association statement on the use of opioids in the treatment of dental pain. 2016. Available at https://www.ada.org/en/about-the-ada/ada-positions-policies-and-statements/substance-use-disorders

American Dental Association ADA adopts interim opioids policy 2018. Available at https://www.ada.org/en/publications/ada-news/2018-archive/march/ada-adopts-interim-opioids-policy

American Pain Society. Principles of Analgesic Use. 7th ed. Chicago, IL: American Pain Society; 2016.

Aminoshariae A, Kulild JC, Donaldson M, Hersh EV. Evidence-based recommendations for analgesic efficacy to treat pain of endodontic origin: A systematic review of randomized controlled trials. J Am Dent Assoc. 2016;147(10):826-839.[PubMed 27475974]

Aurora RN, Kristo DA, Bista SR, et al; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. Sleep. 2012;35(8):1039-1062.[PubMed 22851801]

Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin Pharmacol Ther. 2009;85(6):596-599.[PubMed 19279562]

Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436-442. doi: 10.1200/JCO.2015.61.0733.[PubMed 26644526]

Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc. 2015;90(6):828-842. doi: 10.1016/j.mayocp.2015.04.003.[PubMed 26046416]

Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3)(suppl 1):S12-S18. doi: 0.1016/j.amjmed.2012.12.001.[PubMed 23414717]

Busse J; National Pain Center. The 2017 Canadian guideline for opioids for chronic non-cancer pain. http://nationalpaincentre.mcmaster.ca/guidelines.html. Published 2017. Accessed September 13, 2018[PubMed 28483845]

Centers for Disease Control and Prevention (CDC). Common elements in guidelines for prescribing opioids for chronic pain. https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf. Published 2015. Accessed September 13, 2018.

Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain. 2009;10(2):113-130.[PubMed 19187889]

ConZip (tramadol) [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals; September 2018.

Doroschak AM, Bowles WR, Hargreaves KM. Evaluation of the combination of flurbiprofen and tramadol for management of endodontic pain. J Endod. 1999;25(10):660-663.[PubMed 10687523]

Dow K, Ordean A, Murphy-Oikonen J, et al. Neonatal Abstinence Syndrome Clinical Practice Guidelines for Ontario. J Popul Ther Clin Pharmacol. 2012;19(3):e488-e506.[PubMed 23241498]

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016 [published correction appears in MMWR Recomm Rep. 2016;65(11):295]. MMWR Recomm Rep. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.[PubMed 26987082]

Durela (tramadol) [product monograph]. Mississauga, Ontario, Canada: Cipher Pharmaceuticals Inc; December 2016.

Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7(7):592-593.[PubMed 16926116]

Eassa BI, El-Shazly MA. Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. Asian J Androl. 2013;15(1):138-142. doi: 10.1038/aja.2012.96.[PubMed 23103596]

Fricke JR Jr, Hewitt DJ, Jordan DM, Fisher A, Rosenthal NR. A double-blind placebo-controlled comparison of tramadol/acetaminophen and tramadol in patients with postoperative dental pain. Pain. 2004;109(3):250-257.[PubMed 15157685]

Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med. 2015;175(2):186-193. doi: 10.1001/jamainternmed.2014.6512.[PubMed 25485799]

Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: A randomised placebo-controlled clinical trial. Arab J Urol. 2013;11(4):392-397. doi: 10.1016/j.aju.2013.05.003.[PubMed 26558110]

Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385-1396.[PubMed 22937989]

Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.[PubMed 15509185]

Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg. 2018;267(3):468-472. doi: 10.1097/SLA.0000000000002198.[PubMed 28267689]

Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.[PubMed 22563589]

Hudak ML, Tan RC; Committee On Drugs, et al. Neonatal Drug Withdrawal. Pediatrics. 2012;129(2):e540-e560.[PubMed 22291123]

Hull MJ, Griggs D, Knoepp SM, et al. Postmortem Urine Immunoassay Showing False-Positive Phencyclidine Reactivity in a Case of Fatal Tramadol Overdose. Am J Forensic Med Pathol. 2006;27(4):359-362.

Ilett KF, Paech MJ, Page-Sharp M, et al. Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. Br J Clin Pharmacol. 2008;65(5):661-666.[PubMed 18294329]

Kahan M, Wilson L, Mailis-Gagnon A, et al, “Canadian Guideline For Safe and Effective Use of Opioids For Chronic Noncancer Pain: Clinical Summary For Family Physicians. Part 2: Special Populations,” Can Fam Physician, 2011, 57(11):1269-76, e419-28.[PubMed 22084456]

Kaynar M, Kilic O, Yurdakul T. On-demand tramadol hydrochloride use in premature ejaculation treatment. Urology. 2012;79(1):145-149. doi: 10.1016/j.urology.2011.09.031.[PubMed 22088571]

Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60(4):241-244.[PubMed 10221285]

Mehrvarzfar P, Abbott PV, Saghiri MA, Delvarani A, Asgar K, Lotfi M, Karamifar K, Kharazifard MJ, Khabazi H. Effects of three oral analgesics on postoperative pain following root canal preparation: a controlled clinical trial. Int Endod J. 2012;45(1):76-82.[PubMed 21902704]

Mishra H, Khan FA. A double-blind, placebo-controlled randomized comparison of pre and postoperative administration of ketorolac and tramadol for dental extraction pain. J Anaesthesiol Clin Pharmacol. 2012;28(2):221-225.[PubMed 22557747]

Montgomery A, Hale TW; Academy of Breastfeeding Medicine. ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2012. Breastfeed Med.2012;7(6):547-553.[PubMed 23215911]

Moore PA, Ziegler KM, Lipman RD, Aminoshariae A, Carrasco-Labra A, Mariotti A. Benefits and harms associated with analgesic medications used in the management of acute dental pain: an overview of systematic reviews. J Am Dent Assoc. 2018;149(4):256-265.e3.[PubMed 29599019]

Pino CA, Covington M. Prescription of opioids for acute pain in opioid naïve patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 13, 2018.

Ralivia (tramadol) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; March 2018.

Rosenquist R. Use of opioids in the management of chronic non-cancer pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 14, 2018.

Rudisill TM, Zhu M, Davidov D, et al. Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and older: a case-crossover study. BMC Res Notes.2016a;9:166.[PubMed 26979111]

Rudisill TM, Zhu M, Kelley GA, Pilkerton C, Rudisill BR. Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accid Anal Prev.2016b;96:255-270.[PubMed 27569655]

Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796-809.[PubMed 23979084]

Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006;26(1):27-31.[PubMed 16415702]

Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008;5(1):188-193.[PubMed 17362279]

Salman S, Sy SK, Ilett KF, Page-Sharp M, Paech MJ. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. Eur J Clin Pharmacol. 2011;67(9):899-908.[PubMed 21394525]

Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 13, 2018.

Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG; Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977-986. doi: 10.1016/j.mayocp.2013.06.016.[PubMed 24001490]

Silber MH, Becker PM, Buchfuhrer MJ, et al; Scientific and Medical Advisory Board, Restless Legs Syndrome Foundation. The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc. 2018;93(1):59-67. doi: 10.1016/j.mayocp.2017.11.007.[PubMed 29304922]

Tramadol Hydrochloride ER tablets [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals; September 2018.

Tramadol Hydrochloride ER capsule 150 mg [prescribing information]. Los Angeles, CA: STA3 LLC; May 2015.

Tridural (tramadol) [product monograph]. Saint-Laurent, Quebec, Canada: Paladin Labs Inc; April 2018.

Ultram (tramadol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; September 2018.

Ultram (tramadol) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; January 2017.

Ultram ER (tramadol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2017.

Vetrugno R, La Morgia C, D’Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22(3):424-427.[PubMed 17230457]

Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;5:CD012508. doi: 10.1002/14651858.CD012508.pub2.[PubMed 28510996]

Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593.[PubMed 27856776]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/[PubMed 23215911]

Zytram XL (tramadol) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; May 2017.

Brand Names: International

Adamon (AR, CR, DO, GT, HN, NI, PA, PY, SV); Adolonta (ES); Amanda (TH); Analab (LK, MY, TH); Betram (PH); Biodalgic (FR); Bongesic (CR, DO, GT, HN, NI, PA, SV); Calmador (AR); Calmol (UY); Contramal (BE, EG, FR, HU, IN, IT, TR); Contramal LP (FR); Dolodol (ES); Dolonil (BD); Dolotral (PH); Dolpaz (PH); Dolzam (BE, LU); Domadol (ET, ZW); Dromadol (GB); Durodor Retard (MX); Durotram XR (AU); E-Dol (ZW); Eufindol (CL); Kontram XL SR (KR); Koridol (HK); Lucidol (BD); Lumidol (HR); Mabron (AE, BH, CY, ET, IQ, IR, JO, KW, LB, LV, LY, MY, OM, SA, SG, SY, YE); Mabron SR (LV); Mandolgin (DK); Monoalgic LP (FR); Monotramal LP (FR); Newtram (KR); Noax (SI); Nobligan (NO, SE); Nobligan Retard (NO); Nomal (QA); Onetram (JP); Orasic (ID); Paxilfar (PT); Pengesic (SG); Pengesic SR (HK); Pengesic SR 100 (ET); Potendol SR (KR); Predxal (VN); Radol (ID); Ramado Retard (KR); Rivadol (EG); Romadol (BD); Sefmal (HK, SG, VN); Seminac (ID); Seminac Continus (ID); Sensitram (BR); Syndol (LK); Tadol (SI); Takadol (FR); Tamolan (TH); Topalgic (FR); Trabilin (BB, BM, BS, BZ, CR, DO, GT, GY, HN, JM, NI, PA, SR, SV, TT); Tradmin (ZW); Tradol (ET, ZW); Tradol-Puren (DE); Tradolan (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SE, SY, YE); Tradonal (BE, PH); Tradorec XL (GB, IE); Tralgit SR (SK); Trama Inj (IL); Tramada (MY); Tramadex (IL); Tramadol Slovakofarma (HU); Tramadolor (LT); Tramagetic (DE); Tramagit (DE); Tramahexal (ZA); Tramake (IE); Tramal (AE, AT, AU, BF, BH, BJ, CH, CI, CN, CO, CR, CU, CY, CZ, DE, DO, EC, EE, EG, ET, FI, GH, GM, GN, GR, GT, HN, HR, IL, IQ, IR, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SK, SL, SN, SV, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM); Tramal Long (EC); Tramal Retard (AE, BH, KW, LB, NL, QA, SA); Tramal SR (NZ); Tramalgin (BG); Tramazac (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM); Tramaze (PH); Tramcontin (CN); Tramed (TW); Tramedo (AU); Tramedo SR (AU); Tramica (ZW); Tramol (LK); Tramundin Retard (AE, KW); Tramundin retard (BH); Trasic (LK); Trasik (ID); TRD-Contin (IN); Trexol (MX); Tridol (KR); Trol (BD); Ultradol (BD); Unitral (PH); Vesnon-V (TH); Zamadol (BR, GB); Zamudol (FR); Zodol (CL, PY); Zudol (LK); Zydol (AU, GB, IE); Zydol SR (AU); Zydol XL (GB); Zytram BD (NZ); Zytram XL (NZ); Zytram XL SR (KR)

Tramadol (Patient Education – Adult Medication)
You must carefully read the “Consumer Information Use and Disclaimer” below in order to understand and correctly use this information
Pronunciation

(TRA ma dole)

Brand Names: US

ConZip; Ultram; Ultram ER [DSC]

Brand Names: Canada

Durela; Ralivia; Tridural; Ultram; Zytram XL

Warning
  • All products:
  • This drug may be habit-forming with long-term use.
  • This drug is a strong pain drug that can put you at risk for addiction, abuse, and misuse. Misuse or abuse of this drug can lead to overdose and death. Talk with your doctor.
  • You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.
  • This drug may cause very bad and sometimes deadly breathing problems. Call your doctor right away if you have slow, shallow, or trouble breathing.
  • The chance of very bad and sometimes deadly breathing problems may be greater when you first start this drug or anytime your dose is raised.
  • Even one dose of this drug may be deadly if it is taken by someone else or by accident, especially in children. If this drug is taken by someone else or by accident, get medical help right away.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Using this drug for a long time during pregnancy may lead to withdrawal in the newborn baby. This can be life-threatening. Talk with the doctor.
  • This drug has an opioid drug in it. The use of opioid drugs along with a benzodiazepine drug or other drugs that may make you drowsy or slow your actions has led to very bad side effects. Side effects that have happened include slowed or trouble breathing and deaths. Benzodiazepine drugs include drugs like alprazolam, diazepam, and lorazepam. Benzodiazepine drugs are used to treat many health problems like anxiety, trouble sleeping, or seizures. Talk with the doctor.
  • Many drugs interact with this drug and can raise the chance of side effects like deadly breathing problems. Talk with your doctor and pharmacist to make sure it is safe to use this drug with all of your drugs.
  • Do not take with alcohol or products that have alcohol. Unsafe and sometimes deadly effects may happen.
  • Get medical help right away if you feel very sleepy, very dizzy, or if you pass out. Caregivers or others need to get medical help right away if the patient does not respond, does not answer or react like normal, or will not wake up.
  • Children:
  • This drug is not approved for use in children. Do not give to a child younger than 12 years of age. Children between 12 and 18 years of age who are very overweight or have certain other health problems like sleep apnea or other lung or breathing problems must not use this drug. If your child has been given this drug, ask the doctor for information about the benefits and risks.
  • Some children have had very bad and sometimes deadly breathing problems when using tramadol after surgery to remove tonsils or adenoids. Do not give to a child younger than 18 years of age who has had surgery to remove tonsils or adenoids. Talk with your child’s doctor.
  • All extended-release products:
  • Swallow whole. Do not chew, break, crush, or dissolve before swallowing. Doing these things can cause very bad side effects and death.
What is this drug used for?
  • It is used to ease pain.
What do I need to tell my doctor BEFORE I take this drug?
  • If you have an allergy to tramadol or any other part of this drug.
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If you have any of these health problems: Lung or breathing problems like asthma, trouble breathing, or sleep apnea; high levels of carbon dioxide in the blood; or stomach or bowel block or narrowing.
  • If you have any of these health problems: Kidney disease or liver disease.
  • If you have thoughts of suicide or if you have ever had alcohol or other drug abuse or dependence.
  • If you have been told by your doctor that you are a rapid metabolizer of some drugs.
  • If you have recently drunk a lot of alcohol or taken a big amount of drugs that may slow your actions like phenobarbital or some pain drugs like oxycodone.
  • If you are taking carbamazepine.
  • If you are taking another drug that has the same drug in it.
  • If you are taking any of these drugs: Buprenorphine, butorphanol, nalbuphine, or pentazocine.
  • If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson’s disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure.
  • If you are taking any of these drugs: Linezolid or methylene blue.
  • If you are breast-feeding. Do not breast-feed while you take this drug.
  • This is not a list of all drugs or health problems that interact with this drug.
  • Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
What are some things I need to know or do while I take this drug?
  • All products:
  • Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
  • Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
  • To lower the chance of feeling dizzy or passing out, rise slowly if you have been sitting or lying down. Be careful going up and down stairs.
  • Very bad and sometimes deadly allergic side effects have rarely happened. Talk with your doctor.
  • Do not take more than what your doctor told you to take. Taking more than you are told may raise your chance of very bad side effects.
  • Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.
  • This drug may raise the chance of seizures. The chance may be higher in people who have certain health problems, use certain other drugs, or drink a lot of alcohol. Talk to your doctor to see if you have a greater chance of seizures while taking this drug.
  • If you have been taking this drug for a long time or at high doses, it may not work as well and you may need higher doses to get the same effect. This is known as tolerance. Call your doctor if this drug stops working well. Do not take more than ordered.
  • This drug may affect how much of some other drugs are in your body. If you are taking other drugs, talk with your doctor. You may need to have your blood work checked more closely while taking this drug with your other drugs.
  • Long-term use of an opioid drug like this drug may lead to lower sex hormone levels. This may lead to signs like change in sex ability in men, no menstrual period in women, lowered interest in sex, or fertility problems. Call your doctor if you have any of these signs.
  • Taking an opioid drug like this drug may lead to a rare but very bad adrenal gland problem. Call your doctor right away if you have very bad dizziness or passing out, very bad upset stomach or throwing up, or if you feel less hungry, very tired, or very weak.
  • If you are 65 or older, use this drug with care. You could have more side effects.
  • This drug may cause harm to the unborn baby if you take it while you are pregnant. If you are pregnant or you get pregnant while taking this drug, call your doctor right away.
  • All extended-release products:
  • Do not stop taking this drug all of a sudden without calling your doctor. You may have a greater risk of signs of withdrawal. If you need to stop this drug, you will want to slowly stop it as ordered by your doctor.
  • All other products:
  • If you have been taking this drug on a regular basis and you stop it all of a sudden, you may have signs of withdrawal. Do not stop taking this drug all of a sudden without calling your doctor. Tell your doctor if you have any bad effects.
What are some side effects that I need to call my doctor about right away?
  • WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.
  • Very bad dizziness or passing out.
  • Feeling confused.
  • Seizures.
  • Feeling very tired or weak.
  • Chest pain or pressure or a fast heartbeat.
  • Trouble passing urine.
  • Passing urine more often.
  • Trouble breathing, slow breathing, or shallow breathing.
  • Noisy breathing.
  • Feeling very sleepy.
  • Change in eyesight.
  • A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with drugs for depression, migraines, or certain other drugs. Call your doctor right away if you have agitation; change in balance; confusion; hallucinations; fever; fast or abnormal heartbeat; flushing; muscle twitching or stiffness; seizures; shivering or shaking; sweating a lot; very bad diarrhea, upset stomach, or throwing up; or very bad headache.
  • A very bad skin reaction (Stevens-Johnson syndrome/toxic epidermal necrolysis) may happen. It can cause very bad health problems that may not go away, and sometimes death. Get medical help right away if you have signs like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in your mouth, throat, nose, or eyes.
What are some other side effects of this drug?
  • All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
  • Constipation.
  • Diarrhea.
  • Dizziness.
  • Feeling sleepy.
  • Dry mouth.
  • Headache.
  • Itching.
  • Upset stomach or throwing up.
  • Not able to sleep.
  • Feeling tired or weak.
  • Flushing.
  • These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
  • You may report side effects to your national health agency.
How is this drug best taken?
  • Use this drug as ordered by your doctor. Read all information given to you. Follow all instructions closely.
  • All products:
  • Take by mouth only.
  • Do not inject or snort this drug. Doing any of these things can cause very bad side effects like trouble breathing and death from overdose.
  • Tablets and liquid (suspension):
  • Take with or without food. Take with food if it causes an upset stomach.
  • Liquid (suspension):
  • Shake well before use.
  • Measure liquid doses carefully. Use the measuring device that comes with this drug. If there is none, ask the pharmacist for a device to measure this drug.
  • Do not use a household teaspoon or tablespoon to measure this drug. Doing so could lead to the dose being too high.
  • All extended-release products:
  • Swallow whole. Do not chew, break, or crush.
  • Take this drug with or without food. Some products need to be taken the same way each time, either always with food or always without food. Be sure you know how to take your product with regard to food. If you are not sure how to take your product with regard to food, talk with your doctor or pharmacist.
  • Take this drug at the same time of day.
  • To gain the most benefit, do not miss doses.
  • Do not use for fast pain relief or on an as needed basis.
  • Do not use for pain relief after surgery if you have not been taking drugs like this drug.
  • If you have trouble swallowing, talk with your doctor.
What do I do if I miss a dose?
  • All extended-release products:
  • Take a missed dose as soon as you think about it.
  • If it is close to the time for your next dose, skip the missed dose and go back to your normal time.
  • Do not take 2 doses at the same time or extra doses.
  • All other products:
  • If you take this drug on a regular basis, take a missed dose as soon as you think about it.
  • If it is close to the time for your next dose, skip the missed dose and go back to your normal time.
  • Do not take 2 doses at the same time or extra doses.
  • Many times this drug is taken on an as needed basis. Do not take more often than told by the doctor.
How do I store and/or throw out this drug?
  • All products:
  • Store at room temperature.
  • Store in a dry place. Do not store in a bathroom.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.
  • Liquid (suspension):
  • Be sure you know how long you can store this drug before you need to throw it away.
General drug facts
  • If your symptoms or health problems do not get better or if they become worse, call your doctor.
  • Do not share your drugs with others and do not take anyone else’s drugs.
  • Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
  • Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
  • Some drugs may have another patient information leaflet. If you have any questions about this drug, please talk with your doctor, nurse, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.